Reaction was mixed to the announcement on Thursday by a coalition of U.S. racetracks to partially phase out race-day administration of the anti-bleeding diuretic furosemide (Lasix), beginning with 2-year-olds racing in 2020 and in stakes races beginning in 2021.
Those supporting the initiative include all tracks owned or operated by Churchill Downs Incorporated (CDI), the New York Racing Association, Inc. (NYRA) and The Stronach Group as well as Del Mar, Keeneland, Lone Star Park and Remington Park, Los Alamitos Racecourse (Thoroughbreds), Oaklawn Park and Tampa Bay Downs. Breeders’ Cup Limited, the Thoroughbred Owners and Breeders’ Association (TOBA) and its American Graded Stakes Committee and the Kentucky Thoroughbred Association also signed on in support of the proposal.
To Read Paulick Report Article
